Both in Biotechnology
Vericel vs Recursion Pharmaceuticals
Over the past year VCEL returned +11.9% and RXRX returned −32.4%; their daily moves had a correlation of 0.28.
VCEL +11.9% RXRX −32.4%Growth of $1, one year, split-adjusted
| Metric | VCEL | RXRX |
|---|---|---|
| Price | $41.09 | $3.68 |
| Market cap | $2.10B | $2.20B |
| Today | +1.43% | −3.92% |
| 1 month | 0.0% | −23.0% |
| 6 months | +11.6% | +9.2% |
| Year to date | +14.1% | −10.0% |
| 1 year | +17.2% | −33.3% |
| Revenue growth (YoY) | +22.5% | +258.5% |
| Gross margin | 72.8% | 45.9% |
| Net margin | 2.8% | −641.6% |
| P/E (TTM) | 86.9× | — |
| Price / sales | 6.9× | 32.2× |
| Net cash | $162.5M | $538.0M |
| Dividend yield | — | — |
| Volatility (60d) | 32.8% | 95.4% |
| Short % of float | 11.1% | 37.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).